BERLIN, December 5 /PRNewswire-FirstCall/ -- Schering AG, Germany is reviewing strategic alternatives for its CIS bio International radiopharmaceutical business. This review is part of Schering’s FOCUS initiative, which entails a comprehensive review of strategic, operational and organizational aspects to enhance profitability. This includes discussions with several parties who are interested in acquiring its CIS bio International radiopharmaceutical business. If such a transaction would be executed it would have a negative one-time effect on the result. The CIS bio International radiopharmaceutical business has approximately 750 employees and generated total sales of approximately EUR 120 million in 2004.
“We are in the process of re-aligning our strategy in the area of Diagnostic Imaging,” said Dr. Karin Dorrepaal, member of the Executive Board of Schering AG, responsible for Diagnostic Imaging. “We intend to focus on innovative diagnostic fields of magnetic resonance imaging, computer tomography, optical and molecular imaging.”
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Find additional information at: www.schering.de/eng
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Your contacts at Corporate Communication:
Media Relations: Oliver Renner , T: +49-30-468-124-31, oliver.renner@schering.de.
Investor Relations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
Schering AG
CONTACT: Media Relations: Oliver Renner , T: +49-30-468-124-31,oliver.renner@schering.de. Investor Relations: Peter Vogt, T:+49-30-468-128-38, peter.vogt@schering.de
